Ionis Pharmaceuticals, Inc. (LON:0JDI)

Market Cap	8.81B +113.8%
Revenue (ttm)	701.18M +33.8%
Net Income	-283.37M
EPS	-1.77
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19
Average Volume	510
Open	72.00
Previous Close	71.73
Day's Range	70.71 - 72.36
52-Week Range	24.11 - 86.72
Beta	0.36
RSI	33.12
Earnings Date	Apr 29, 2026

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1989
• Employees: 1,402
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0JDI

Financial Performance

In 2025, Ionis Pharmaceuticals's revenue was $943.71 million, an increase of 33.83% compared to the previous year's $705.14 million. Losses were -$381.39 million, -15.97% less than in 2024.

Financial numbers in USD